Overview

• Rosen Law Firm, Levi & Korsinsky, and Faruqi & Faruqi issued fresh notices calling on Altimmune investors to consider seeking lead-plaintiff status by October 6, 2025.
• The putative class covers purchasers of Altimmune securities from August 10, 2023 through June 25, 2025.
• Plaintiffs allege the company created inflated expectations for the IMPACT Phase 2b MASH topline results despite a placebo effect that undercut statistical significance on the primary fibrosis endpoint.
• Altimmune’s shares fell from $7.71 on June 25, 2025 to $3.61 on June 26, 2025, a reported one-day decline of 53.2% following the topline announcement.
• No class has been certified, and the firms note investors are not represented by counsel unless they retain one, with participation offered on a contingency-fee basis.